Development of peptide-based lineage-specific serology for chronic Chagas disease: geographical and clinical distribution of epitope recognition. by Bhattacharyya, Tapan et al.
Bhattacharyya, T; Falconar, AK; Luquetti, AO; Costales, JA; Gri-
jalva, MJ; Lewis, MD; Messenger, LA; Tran, TT; Ramirez, JD; Guhl,
F; Carrasco, HJ; Diosque, P; Garcia, L; Litvinov, SV; Miles, MA
(2014) Development of Peptide-based lineage-specific serology for chronic
chagas disease: geographical and clinical distribution of epitope recog-
nition. PLoS neglected tropical diseases, 8 (5). e2892. ISSN 1935-
2727 DOI: 10.1371/journal.pntd.0002892
Downloaded from: http://researchonline.lshtm.ac.uk/1775867/
DOI: 10.1371/journal.pntd.0002892
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
Development of Peptide-Based Lineage-Specific
Serology for Chronic Chagas Disease: Geographical and
Clinical Distribution of Epitope Recognition
Tapan Bhattacharyya1*, Andrew K. Falconar2, Alejandro O. Luquetti3, Jaime A. Costales4,
Mario J. Grijalva4,5, Michael D. Lewis1, Louisa A. Messenger1, Trang T. Tran1, Juan-David Ramirez6,
Felipe Guhl7, Hernan J. Carrasco8, Patricio Diosque9, Lineth Garcia10, Sergey V. Litvinov11,
Michael A. Miles1
1 Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom, 2Departamento de Medicina, Universidad del
Norte, Barranquilla, Colombia, 3 Laboratorio de Chagas, Hospital das Clinicas, Universidade Federal de Goia´s, Goiaˆnia, Goias, Brazil, 4Centro de Investigacio´n en
Enfermedades Infecciosas, Escuela de Biologı´a, Pontificia Universidad Cato´lica del Ecuador, Quito, Ecuador, 5 Tropical Disease Institute, Department of Biomedical
Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, United States of America, 6 Facultad de Ciencias Naturales y Matema´ticas, Universidad
del Rosario, Bogota´, Colombia, 7Centro de Investigaciones en Microbiologı´a y Parasitologı´a Tropical, Universidad de los Andes, Bogota´, Colombia, 8Universidad Central
de Venezuela Instituto de Medicina Tropical, Caracas, Venezuela, 9Unidad de Epidemiologı´a Molecular, Instituto de Patologı´a Experimental, Consejo Nacional de
Investigaciones Cientı´ficas y Te´cnicas (CONICET), Universidad Nacional de Salta, Salta, Argentina, 10 Facultad de Medicina, Universidad Mayor de San Simo´n, Cochabamba,
Bolivia, 11Aptum Biologics Ltd, Southampton, United Kingdom
Abstract
Background: Chagas disease, caused by infection with the protozoan Trypanosoma cruzi, remains a serious public health
issue in Latin America. Genetically diverse, the species is sub-divided into six lineages, known as TcI–TcVI, which have
disparate geographical and ecological distributions. TcII, TcV, and TcVI are associated with severe human disease in the
Southern Cone countries, whereas TcI is associated with cardiomyopathy north of the Amazon. T. cruzi persists as a chronic
infection, with cardiac and/or gastrointestinal symptoms developing years or decades after initial infection. Identifying an
individual’s history of T. cruzi lineage infection directly by genotyping of the parasite is complicated by the low parasitaemia
and sequestration in the host tissues.
Methodology/Principal Findings: We have applied here serology against lineage-specific epitopes of the T. cruzi surface
antigen TSSA, as an indirect approach to allow identification of infecting lineage. Chagasic sera from chronic patients from a
range of endemic countries were tested by ELISA against synthetic peptides representing lineage-specific TSSA epitopes
bound to avidin-coated ELISA plates via a biotin labelled polyethylene glycol-glycine spacer to increase rotation and ensure
each amino acid side chain could freely interact with their antibodies. 79/113 (70%) of samples from Brazil, Bolivia, and
Argentina recognised the TSSA epitope common to lineages TcII/TcV/TcVI. Comparison with clinical information showed
that a higher proportion of Brazilian TSSApep-II/V/VI responders had ECG abnormalities than non-responders (38% vs 17%;
p,0.0001). Among northern chagasic sera 4/20 (20%) from Ecuador reacted with this peptide; 1/12 Venezuelan and 1/34
Colombian samples reacted with TSSApep-IV. In addition, a proposed TcI-specific epitope, described elsewhere, was
demonstrated here to be highly conserved across lineages and therefore not applicable to lineage-specific serology.
Conclusions/Significance: These results demonstrate the considerable potential for synthetic peptide serology to
investigate the infection history of individuals, geographical and clinical associations of T. cruzi lineages.
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Introduction
Chagas disease (South American trypanosomiasis) is still
considered to be the most important parasitic disease in Latin
America, despite notable success with control of household
infestation by the triatomine insect vectors. Up to 8 million
people are estimated to be chronically infected with the causative
agent Trypanosoma cruzi, of whom at least 30% are likely to develop
chagasic cardiomyopathy, in some cases with megasyndromes of
the intestinal tract [1,2]. Vector borne transmission is usually by
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contamination of mucous membranes or abraded skin with T. cruzi
infected triatomine faeces and sporadic oral outbreaks occur due
to triatomine contamination of food [3]. Infection can also be
propagated by congenital transmission and blood or organ
donation, and this may arise among migrant populations far
beyond the endemic regions in Latin America [4].
The species T. cruzi is remarkably diverse genetically and is
currently described as comprising six distinct lineages or discrete
typing units (DTUs, TcI-TcVI) [5]. The six lineages have complex
disparate but partially overlapping geographical and ecological
distributions and are circumstantially associated with different
epidemiological features [6,7]. TcI is the principal agent North of
the Amazon, in association with chagasic heart disease but where
megasyndromes are considered to be rare. TcII is one of three
principal agents of Chagas disease in the Southern Cone region of
South America, where chagasic cardiomyopathy, megaoesophagus
and megacolon are found. TcIII is seldom isolated from humans
but is widely distributed with the natural armadillo host Dasypus
novemcinctus. TcIV is a sporadic secondary agent of Chagas disease
in Venezuela [8]. TcV and TcVI, like TcII, are also agents of
Chagas in the Southern Cone region, and are known to be
relatively recent hybrids of TcII and TcIII [7,9].
Parasitological diagnosis in the acute phase of T. cruzi infection
is by microscopy of fresh blood films, thin blood films, thick blood
films or by haematocrit centrifugation and examination of the
buffy coat, the latter being recommended particularly for
congenital cases. In the chronic phase recovery of live organisms
may be attempted by multiple blood cultures or xenodiagnosis
with colony bred triatomine bugs but with limited sensitivities, or
parasite DNA may be detectable by amplification.
Serological diagnosis of T. cruzi infection is usually performed by
either indirect immunofluorescence (IFAT) or indirect haemaglu-
tination (IHA) or enzyme-linked immunosorbent assay (ELISA),
giving .94% sensitivity and specificity [2]. There are several
commercially available diagnostic kits, including rapid lateral flow
tests but sensitivities may not be equivalent, particularly when they
are used in regions where non-homologous genetic lineages of T.
cruzi are prevalent [8–10]. These serological methods give no
information on the genetic lineage or lineages that a patient
carries, and are not designed for that purpose.
A key objective of Chagas research therefore remains to follow
up in detail the circumstantial evidence of a relationship between
infecting T. cruzi lineage and the clinical outcome [6,7,11].
However, such analysis is complex and vulnerable to multiple
confounders, including diversity of host susceptibility. Even if T.
cruzi isolates can be recovered from the infected blood by
parasitological diagnosis or if DNA can be amplified from blood,
genotyping methods [12,13] do not provide an entire profile of the
infecting lineages in an individual patient, because distinct T. cruzi
lineages may be sequestered in the tissues [14]. An approach to
overcoming this limitation is to identify infecting T. cruzi lineage in
a more indirect way. One strategy to achieve this is by serological
detection of antibodies that are produced in response to lineage-
specific antigens.
Di Noia et al [15] described the trypomastigote small surface
antigen (TSSA), encoded by a member of the TcMUCIII mucin
gene family, expressed on the mammalian bloodstream trypomas-
tigote stage of the T. cruzi life cycle. The authors reported that
TSSA is dimorphic in sequence, with TSSA-I being present in
TcI, and TSSA-II found in TcII-TcVI. On the basis of this finding
the authors pioneered lineage-specific serology for Chagas disease
through application of a TSSA-II recombinant antigen to serology
with patients from the Southern Cone region of South America.
Chagasic patients were only TSSA-II seropositive, which led to the
suggestion that TcI could be benign. However, this suggestion was
in conflict with the geographical predominance of TcI North of
the Amazon and the acute and chronic clinical presentations of
known TcI infections [16,17]. In subsequent publications E. coli-
produced recombinant TSSA proteins have been used more
widely for serology with humans and animals [18–23].
We have previously analysed TSSA diversity among a panel of
T. cruzi isolates representing a broad geographical and ecological
range of lineages TcI-TcVI [24]. We found a greater lineage-
specific diversity than had previously been described. Lineages
TcII, TcV, and TcVI were shown to share a common TSSA
sequence. However, in both of the hybrid lineages TcV and TcVI
we found that two TSSA alleles were present at an heterozygous
locus within the polymorphic epitope: one haplotype was shared
with TcII and in the second haplotype a Thr was replaced by Ala
at position 44 of the protein. Lineage-specific TSSA sites were also
found in TcIII and TcIV strains [24]. Ca´nepa et al [25] suggested
a functional significance for this diversity in that the TcII/TcV/
TcVI form of TSSA, but not the TcI form, has the property of
binding surface receptor(s) and inducing signalling pathways in
host cells prior to parasite internalisation.
Recently, Mendes et al [26] used a bioinformatic analysis of the
reference genome of the TcVI strain CL Brener [27] to identify
candidate peptides for differential screening with sera from mice
experimentally infected with single, known T. cruzi lineages. A
resultant peptide, derived from a putative RNA-binding protein,
was reported to be applicable for TcI serology [26].
Here, we have used our expanded knowledge of the range of
TSSA diversity to design and synthesise lineage-specific peptides.
We assess the capacity of these peptides to provide antigens for
lineage-specific serology by ELISA and thus reveal which lineages
have infected individual patients during their lifetime. Further-
more, we examine the geographical and clinical distribution of
recognition of the synthetic peptide epitopes. In addition, we also
investigate the diversity of the gene coding for the peptide
described [26] as applicable for TcI-specific serology.
Author Summary
Chagas disease remains a significant public health issue in
Latin America. Caused by the single-celled parasite
Trypanosoma cruzi, the main route of infection is via
contact with contaminated faeces from blood-sucking
triatomine bugs, but following successful insecticide
spraying campaigns, congenital, food-borne, and transfu-
sion/transplantation routes of infection have become
more relevant. In the absence of successful chemotherapy,
T. cruzi usually persists in the body for life, and in
symptomatic cases may lead to death or debilitation by
heart failure and/or gastrointestinal megasyndromes. As a
species, T. cruzi displays great genetic diversity, and is
subdivided into lineages called TcI - TcVI. Associating T.
cruzi lineage with clinical symptoms is a key goal of Chagas
disease research. Direct isolation and typing of T. cruzi
from chronically infected patients is hampered by the
sequestration of the parasite in host tissues. Identifying
lineage-specific antibodies in serum provides an alterna-
tive approach to determining an individual’s history of
infection. Here, we performed lineage-specific serology
using samples from a range of South American countries.
We show that lineage-specific seropositivity is associated
with geographical distributions and clinical outcome.
These findings have wide implications for further diagnos-
tics development and improved understanding of the
epidemiology of Chagas disease.
Lineage-Specific Serology in Chronic Chagas Disease
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Materials and Methods
Ethics statement
Human sera were collected as part of routine diagnostic
examination, with local institutional ethical approvals, and in
accord with EC ethical standards established as part of the
ChagasEpiNet international collaboration. All human sera were
anonymised and coded by letters and numbers that did not reveal
patient identities. Production of mouse sera adhered to the
European 3Rs policy of Refinement, Reduction and Replacement
(99/167/EG: Council decision of 25/1/99), took place in
authorised animal facilities by licensed staff in agreement with
the European Directive 86/609/EEC, and with review and
approvals under UK Home office regulations [Animals (Scientific
Procedures) Act 1986; project licence number 70/6997 to the
London School of Hygiene and Tropical Medicine].
Mouse and human sera
Mouse sera were from mice previously inoculated intraperito-
neally with 106 organisms from stationary phase cultures
containing infective metacyclic trypomastigotes, of known biolog-
ical clones of T. cruzi representing the lineages. Sera were
separated from whole mouse blood by allowing clotting at room
temperature, overnight storage at 4uC, centrifugation at 120006g
for 10 mins and removal of the supernatant serum. Serum samples
were stored 1:1 with glycerol at 220uC.
Human sera were from chronic cases of Chagas disease,
confirmed by a combination of parasitological and serological
diagnosis. As shown in Table 1, 113 samples were from the
Southern Cone countries, Brazil, Bolivia and Argentina, and 66
samples were from countries North of the Amazon, Colombia,
Ecuador, Venezuela, where TcI has been considered to predom-
inate. Brazilian sera were from patients who had a positive
parasitological diagnosis at the time of serum collection, together
with a full clinical history, their geographical origin, age and sex.
Institutes providing sera were: Hospital das Clinicas, Goiaˆnia,
Brazil; Universidad Mayor de San Simon, Cochabamba, Bolivia;
Universidad Nacional de Salta, Argentina; Universidad Central de
Venezuela, Caracas, Venezuela; Universidad de los Andes,
Bogota´, Colombia; Pontificia Universidad Cato´lica del Ecuador,
Quito, Ecuador. Endemic healthy controls were from the Hospital
das Clinicas, Goiaˆnia, Brazil, and additional controls were 17 sera
from Colombia that were serologically negative to T. cruzi lysate.
Synthesis of lineage-specific peptides
The synthetic peptides were prepared with an amino terminal
biotin molecule linked via a polyethylene glycol-glycine spacer so
that they could be bound to avidin-coated ELISA plates.
Importantly, this method increased their rotation and ensured
that each amino acid side chain could freely interact with
antibodies, as opposed to being adsorbed onto the solid phase
where some amino acid side chains would be unavailable, as
discussed previously [28].
Design of the peptides was based on the T. cruzi TSSA lineage-
specific amino acid sequences previously described [24]; chimeric
peptides comprised by TSSA-I and TSSA-II sequences were also
designed and synthesised (Results; Figure 1). Synthetic peptides
were prepared at the 20 mM scale on 100–200 mesh-size Fmoc-
Cys(Trt) Wang resin (0.5 mmol/g) (856006: Novabiochem, UK)
using a Zinsser Analytic SMPS 350 (Zinsser Analytic, UK) or
Advanced Chemtech Apex 396 (Advanced Chemtech, USA)
robotic multiple peptide synthesizer. Aspartamide formation of
aspartic acid residues was reduced by the use of OMpe-protected
Fmoc-Asp(OMpe)-OH (852104: Novabiochem, UK). The
coupling steps were performed using 0.5 M Fmoc-protected
amino acids diluted in 6.76% (wt/vol) 1-hydroxybenzotriazole
(HOBt)/dimethylformamide (DMF) (Activotec, UK/Rathburn
Chemicals Ltd., UK) activated using 0.5 M N,N,N9,N9-tetra-
methyl-O-(1H-benzotriazol-1-yl)uranium hexafluorophosphate
(HBTU) (851006: Novabiochem, UK) with 1M N,N-diisopropy-
lethylamine (DIPEA) (Rathburn Chemicals Ltd., UK), while the
deprotection steps were performed using 20% (vol/vol) piperi-
dine/DMF (Rathburn Chemicals Ltd., UK). The carboxyl- and
amino- regions flanking the core epitope sequences contained
additional glycine (G) residues to increase rotation (high dihedral
(y against Q) angles) of their carboxyl-terminal cysteine (C) residue
and their amino-terminal spacer and molecular label. Their amino
termini were labelled via a polyethylene glycol (PEG) spacer
(Fig 1A) through sequential couplings with 0.5 M Fmoc-NH-
(PEG)2-COOH (13 atoms or 20 atoms) (851034 or 851031:
Novabiochem, UK) followed by 0.5 M biotin (B4501: Sigma
Aldrich, UK) using the more efficient coupling agent, 0.5 M
N,N,N9,N9-tetramethyl-O-(7-azabenzotriazol-1-yl)uranium hexa-
fluorophosphate (HATU) (851013: Novabiochem, UK) containing
1 M DIPEA. The final peptides were each washed 5 times with
dichloromethane and then methanol (Rathburn Chemicals Ltd.,
UK) before being dried in a freeze-drier (Edwards, UK). Peptide
cleavage was performed by reaction for 3–4 hours using 1% (wt/
vol) phenol, 2% H2O, 2.5% (vol/vol) triisopropyl silane (233781:
Sigma Aldrich, UK) and 2% (vol/vol) 2,29 (ethylenedioxy)
diethanethiol (3,6-dioxa-1,8-octanedithiol (DODT)) (465178: Sig-
ma Aldrich, UK) in trifluoroacetic acid (Rathburn Chemicals Ltd.,
UK) [29]. The cleaved peptides were then precipitated in cold
(0uC) peroxide-free diethyl ether (Rathburn Chemicals Ltd., UK),
centrifuged at 2,0006g; the supernatants were discarded and the
precipitation and centrifugation steps were repeated twice. The
peptides were then dried under a stream of anhydrous argon gas
(BOC, UK) before being stored at 280uC.
For purification each peptide was subsequently dissolved in
500 ml of 2,2,2, trifluoroethanol (T63002: Sigma Aldrich, USA),
made to 5.5 ml with 5% (vol/vol) far UV grade acetonitrile
(Rathburn Chemicals Ltd., UK) in H2O containing 0.1% (vol/vol)
trifluoroacetic acid, and then subjected to reversed-phase HPLC
using a 5 ml injection loop, a 5–95% acetonitrile gradient run at
9 ml/min over 30 min through an ACE C18–300 A˚
250621.2 mm preparative column (ACE-231-2520: Advanced
Chromatography Technologies, UK) in a Beckman Gold prepar-
ative HPLC system (Beckman, USA). The main peaks, detected at
a wavelength of 215 nm, were collected and freeze-dried before
storage at 280uC.
Additionally, peptides TSSApep-II/V/VI, chimera TSSApep-
I/-II, and MenTcI were also synthesised commercially (Geno-
sphere Biotechnologies, Paris, France).
Purified peptides were prepared as 1 mg/ml stock solutions in
PBS and the addition of biotin in the last coupling was assessed by
ELISA. For this assay, 10 mg/ml of each peptide was prepared in
16 carbonate-bicarbonate coating buffer (15 mM Na2CO3,
34 mM NaHCO3, pH 9.6) and added at 50 ml/well to 96-well
ELISA plates (735–0465: Immulon 4HBX, VWR, UK). Plates
were covered with an adhesive sheet and incubated overnight at
4uC. Following three washes with PBS containing 0.05% (vol/vol)
Tween 20 (P7949: Sigma Aldrich, UK) (PBS/T), 200 ml/well
blocking buffer (PBS/2% skimmed milk powder (Premier Inter-
national Foods, Spalding, UK) was added and incubated at 37uC
for 2 hrs. Following three washes, a 1:2000 dilution of peroxidase-
labeled streptavidin (S2438: Sigma Aldrich, UK) in PBS/T
containing 2% skimmed milk powder (PBS/T/M) was added at
50 ml/well, and incubated at 37uC for 1 hour. After washing six
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times with PBS/T, 50 mM phosphate/citrate buffer (pH 5.0)
containing 2 mM o-phenylenediamine HCl (P1526: Sigma
Aldrich, UK) and 0.005% (vol/vol) H2O2 (216763: Sigma Aldrich,
UK) was added at 50 ml/well and the plates were incubated in the
dark at room temperature for 10 minutes. The substrate reactions
were then stopped by the addition of 2M H2SO4 (25 ml/well) and
the absorbance values were determined at a wavelength of 490 nm
(MRX, Dynatech, USA).
Production of whole-cell lysate antigen
T. cruzi was cultured as previously described [30]. For
production of lysate antigen, mid-to-late log phase cultures of a
TcII strain (IINF/PY/00/Chaco23cl4) of T. cruzi were centrifuged
at 8006g for 10 mins at 4uC in an Allegra X-15R benchtop
centrifuge (Beckman Coulter, UK). After washing in PBS, cell
pellets were subjected to 3 cycles of flash-freezing in liquid
nitrogen and thawing in a cold water bath. Cell lysates were then
sonicated for 3630 sec, with intervals on ice, using a Soniprep 150
sonicator (MSE), at 12 m amplitude. Sonicated lysates were
centrifuged at 13000 rpm for 1 min, and the supernatant used
as antigen in ELISA. Protein concentration was determined using
the BCA Protein Assay kit (PN23227: Fisher Scientific, UK).
Lineage-specific peptide ELISA
Immulon 4HBX 96-well flat bottomed ELISA plates were
coated with 1 mg/100 ml/well of avidin (A9275: Sigma, UK)
diluted in 16 carbonate-bicarbonate coating buffer for binding to
lineage-specific peptide, and in separate wells coating was with
TcII T. cruzi lysate at 0.2 mg/100 ml/well to act as a serologically
positive control for each sample. Plates were covered with an
adhesive sheet and incubated overnight at 4uC. The following day,
unbound avidin and lysate were removed, the plate washed three
times with wash buffer PBS/T, then wells were blocked with
200 ml blocking buffer PBS/T/M at 37uC for 2 hrs. Following
three washes, 1 mg/100 ml/well TSSA lineage-specific peptide in
PBS/T/M was incubated with the avidin-coated wells at 37uC for
1 hr. Following three washes, 100 ml/well of a 1:200 dilution of
serum in PBS/T/M was added and incubated at 37uC for 1 hr.
Following six washes, 100 ml/well of donkey anti-human IgG (H+
L)-HRP (709-035–149: Jackson Immunoresearch, Pennsylvania,
USA), diluted 1:5,000 in PBS/T/M was added, and incubated at
37uC for 1 hr. Following six washes, plates were developed and
read as described above, except that the volumes were 100 ml for
substrate and 50 ml for 2M H2SO4. Replica plates were run in
duplicate simultaneously.
Statistical analysis
Cut-off values for ELISAs with human sera and peptides were
calculated from the mean plus 3 standard deviations compared to
the endemic healthy controls from Goiaˆnia, Brazil. Statistical
analysis (2-tailed unpaired t-test) on the Brazilian TSSApep-II/V/
VI seropositives and non-responders was performed using
GraphPad Prism version 4.02 for Windows (GraphPad Software,
San Diego, California, USA).
Analysing diversity of the putative TcI epitope
We designed PCR primers MenTcI FOR (59 ATGCCA-
CAATCGAAACCAAG 39) and MenTcI REV (59 TCACAA-
CAAACGTTTGGCTG 39) (synthesised by Eurofins MWG
Operon, Germany) to amplify the whole open reading frame
(ORF) of the putative RNA–binding protein (Tc00.1047
053511837.129) which was described as containing an epitope
and corresponding peptide applicable for TcI serology [26]. T.
cruzi strains, from which genomic DNA was used as amplification
template, are listed in Table 2. Amplification reactions were
performed in a total volume of 20 ml, and comprised of 16NH4
reaction buffer supplemented with 1.5 mM MgCl2 (Bioline, UK),
200 mM dNTPs (New England Biolabs, UK), 10 pmol of each
primer, and 1 U BioTaq DNA polymerase (Bioline). Amplification
conditions were: 1 cycle of 94uC, 3 mins; 25 cycles of 94uC for
30 secs, 55uC for 30 secs, 72uC for 30 secs; 1 cycle of 72uC for
10 mins. Five microliters of the PCR reaction were analysed by
electrophoresis on 1.5% agarose gels (Bioline); amplification
products were purified from the remaining reaction by precipita-
tion with an equal volume of isopropanol at room temperature,
followed by washing with 70% EtOH, air-drying and resuspension
in ddH2O. Bi-directional DNA sequencing, using each PCR
primer separately at 3.2 pmol, was achieved using a BigDye
Figure 1. TSSA provides potential epitopes that are T. cruzi lineage-specific. [A] Components of the peptides synthesised: N-terminal
biotinylation; PEG spacer; Gly; the lineage-specific sequence; C-terminal Cys. [B] Amino acid sequences of the T. cruzi lineage-specific TSSA potential
epitopes in the synthetic peptides (TSSApep-), with polymorphic residues underlined; for the two chimeric peptides the TSSA-II residues are shown in bold.
doi:10.1371/journal.pntd.0002892.g001
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Terminator v3.1 RR-100 kit (Applied Biosystems, UK) according
to standard protocols. Sequence alignment was performed using
BioEdit software [31]. In parallel, the coding region of the TSSA
gene containing lineage-specific sequences was also sequenced, as
described previously [24], to confirm lineage identity.
Linear B-epitope profiling
Computer analysis of the TSSA-I and the TSSA-II/V/VI
common epitope was performed using EpiQuest-B software (v
2.1.17, Matrix B7.1) from Aptum Biologics Ltd (Southampton,
Hampshire, UK). The algorithm of the program allows prediction
of potential linear B-epitopes and their immunogenicity. The data
were used in graphical format.
Accession numbers
Nucleotide sequences derived in this manuscript are available
under GenBank accession numbers KJ395471 - KJ395493.
Results
TSSA provides potential epitopes specific for each T. cruzi
lineage
The structures and sequences of the peptides synthesised,
indicating the lineage-specific amino acids, are shown in Figure 1,
as based on the comparisons of diversity previously described [24].
In addition to the peptides representing single lineages we
synthesised two chimeric peptides, one with TSSA-I residues at
the N terminus and TSSA-II residues at the C terminus, and the
second with TSSA-II at the N terminus and TSSA-I at the C
terminus (Figure 1B).
Consistent with the known extensive genomic divergence
between TcI and TcII, eight residues differed between their
TSSA potential epitopes. Five and six residues separated TSSA-II
from TSSA-III and TSSA-IV, respectively. Four residues distin-
guished TSSA-I from TSSA-III and two residues separated TSSA-
I from TSSA-IV, in accord with their somewhat greater affinity
with TcI. A single residue differed between the TSSA-II haplotype
shared by TcII, TcV and TcVI and the second haplotype present
at the heterozygous locus in the hybrids TcV and TcVI.
Synthetic peptides are recognised by serum antibodies
Sera from mice experimentally infected with biological clones of
TcII, TcV and TcVI strains recognised TSSApep-II/V/VI in
serology by ELISA, and sera from TcIII and TcIV murine
infections reacted with the corresponding TSSA peptides (Bhat-
tacharyya et al, in preparation), encouraging the evaluation
described here of the diagnostic potential of all the synthetic
peptides with sera from patients with chronic Chagas disease.
Figure 2 shows examples of ELISA plates with T. cruzi lysate
and lineage-specific synthetic peptides as antigens. Sera from
normal healthy endemic controls did not react with the T. cruzi
lysate or with any of the synthetic peptides. Without exception all
Table 2. T. cruzi strains used here for comparative analysis of the ORF containing the reported TcI-applicable peptide (GenBank
accession numbers refer to sequences determined here).
Lineage Strain Origin Host/vector Tc00.1047053511837.129 [26]
a
GenBank
E N S A N P P P P D R S L P T P
TcI MHOM/BR/78/Sylvio-X10/1 Bele´m, Brazil Homo sapiens . . . . . . . . . . . . . . . . KJ395471
MHOM/PE/00/SaxP18 Majes, Peru Homo sapiens . . . . . . . . . . . . . . . . KJ395472
MPHI/BO/00/SJM41 Beni, Bolivia Philander opossum . . . . . . . . . . . . . . . . KJ395473
MDID/BO/00/SMA2 Beni, Bolivia Didelphis marsupialis . . . . . . . . . . . . . . . . KJ395474
MDID/BO/00/SJM37 Beni, Bolivia Didelphis marsupialis . . . . . . . . . . . . . . . . KJ395475
MPHT/BO/00/COTMA47 Cotopachi, Bolivia Phyllotis ocilae . . . . . . . . . . . . . . . . KJ395476
TcII MHOM/CL/00/IVV Cuncumen, Chile Homo sapiens . . . . . . . . . . . . . . . . KJ395477
MHOM/BR/00/Y Sa˜o Paulo, Brazil Homo sapiens . . . . . . . . . . . . . . ST. KJ395478
MHOM/CL/00/CBB Region IV, Chile Homo sapiens . . . . . . . . . . . . . . ST. KJ395479
IINF/BO/00/Tu18 Tupiza, Bolivia Triatoma infestans . . . . . . . . . . . . . . . . KJ395480
IINF/PY/00/Chaco23 Chaco, Paraguay Triatoma infestans . . . . . . . . . . . . . . . . KJ395481
IINF/PY/00/T655 Chaco, Paraguay Triatoma infestans . . . . . . . . . . . . . . . . KJ395482
TcIV IINF/AR/00/LHVA Chaco, Argentina Triatoma infestans . . . . . . . . . . . . . . . . KJ395483
TcV IINF/CL/00/Vinch101 Limari, Chile Triatoma infestans . . . . . . . . . . . . . . . . KJ395484
MHOM/BO/00/92:80 Santa Cruz, Bolivia Homo sapiens . . . . . . . . . . . . . . . . KJ395485
IINF/BR/00/Bug2148 Rio Grande do Sul, Brazil Triatoma infestans . . . . . . . . . . . . . . . . KJ395486
IINF/PY/00/Para6 Paraguari, Paraguay Triatoma infestans . . . . . . . . . . . A . . A . KJ395487
TcVI MHOM/BR/00/CL Brener Rio Grande do Sul, Brazil Triatoma infestans . . . . . . . . . . . . . . . . KJ395488
MHOM/BO/00/P251 Cochabamba, Bolivia Homo sapiens . . . . . . . . . . . . . . . . KJ395489
IINF/PY/00/Chaco17 Chaco, Paraguay Triatoma infestans . . . . . . . . . . . . . . . . KJ395490
IINF/PY/00/Chaco9 Chaco, Paraguay Triatoma infestans . . . . . . . . . . . . . . . . KJ395491
IINF/AR/00/EPV20-1 Chaco, Argentina Triatoma infestans . . . . . . . . . . . . . . . . KJ395492
IINF/CL/00/VFRA Francia, Chile Triatoma infestans . . . . . . . . . . . . . . . . KJ395493
a. = no amino acid change.
doi:10.1371/journal.pntd.0002892.t002
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sera from patients with chronic Chagas disease recognised the T.
cruzi TcII lysate antigen preparation. Figure 2 also provides
examples of sera from Brazil, Argentina and Ecuador that
recognised TSSApep-II/V/VI, indicative of infection with
TcII,TcV or TcVI. A positive result for the epitope derived from
the TcV/VI specific haplotype indicates definite infection with
TcV or TcVI. Some of these sera (e.g. B6 & B10) reacted with
both TSSApep-II/V/VI and TSSApep-V/VI representing the
haplotype restricted to TcV and TcVI, indicating infection with a
hybrid strain, possibly in conjunction with a TcII infection.
Recognition of the TcV and TcVI restricted epitope was never
seen in the absence of recognition of the TSSApep-II/V/VI.
A Venezuelan serum (V4 in Figure 2) recognised TSSApep-IV,
consistent with the known presence of TcIV as a secondary agent
of Chagas disease in Venezuela [16]. However, this serum also
bound to TSSApep-III, which only differs by 2 of 16 residues.
An antibody response to TSSApep-I was exceptional, only two
sera were reactive from the entire set of samples (Table 1) of which
one weak reactor (Argentina A3) is shown in Figure 2.
Chimera TSSApep-I/-II and chimera TSSApep-II/-I were
designed to determine whether the antigenic epitope resided at
the N or C terminus of the peptides. Chimera TSSApep-II/-I was
recognised by 71/83 TSSApep-II/V/VI reactive sera, as demon-
strated for example by Argentine patients A1, A2 and A4 (Figure 2).
In comparison, only 11/83 recognised the chimera TSSApep-I/-II,
indicative that, although not precisely mapped, the dominant region
of the epitope lies towards the N terminus of the peptide and that in
some patients the N terminus is adequate to provide a detectable
epitope. A single TSSApep-IV/TSSApep-III positive serum also
recognised the chimera TSSApep-I/-II peptide.
Four of 186 samples responded to all wells containing peptides;
these were demonstrated to bind non-specifically to avidin in the
absence of peptide, but not to cross react with milk proteins (data
not shown).
Rare recognition of the TSSA-II/V/VI common peptide in
northern South America
The 186 sera from patients with chronic Chagas disease spanned
a geographical range from Argentina to Venezuela. Three Southern
Cone countries were included, where TcII, TcV and TcVI have
been reported to be endemic, and three countries from northern
South America, where TcI is considered to predominate. A
summary of the geographical distribution of the antibody responses
to all the lineage-specific synthetic peptides is shown in Table 1. Of
the sera recognizing TSSApep-II/V/VI, 79 out of 83 were from the
Southern Cone countries and four were from Ecuador. Of these 83
sera, 13 sera also recognised TSSApep-V/VI, 12 from Southern
Cone countries and one of the four sera from Ecuador, indicating
presence of TcV or TcVI, possibly with TcII co-infection.
Independently of the lineage-specific peptides, we also examined
the response to two different chimera peptides, each comprising
different combinations of sequences from TSSApep-I and TSSA-
pep-II/V/VI. Of the Bolivian, Ecuadorean and Argentine sera
which reacted with TSSApep-II/V/VI, all reacted with chimera
TSSApep-II/-I, but only two samples (Ecuadorean) also reacted
with chimera TSSApep-I/-II. In the case of Brazilian samples, of
the 67 that reacted with TSSApep-II/V/VI, 55 reacted with
chimera TSSApep-II/-I, and of these 55, 9 also reacted with
chimera TSSApep-I/-II. Only one sample (Venezuelan) reacted
with chimera TSSApep-I/-II but not with TSSApep-II/V/VI or
chimera TSSApep-II/-I. TSSApep-I failed to detect antibodies,
regardless of origin of the chagasic sera, with the exception of two
sera, one each from Brazil and Argentina. Four sera recognised both
TSSApep-IV and TSSApep-III, consistent with cross-reaction due
to the close similarity between these epitopes.
The country by country distribution of antibody recognition of
the peptides is given in Table 1. ELISA cut-offs and absorbance
values for each lineage-specific peptide are shown in Figure 3.
Each data point represents the mean A490 readout of duplicate
assays of the serum sample with the lineage specific peptides. In
Figure 3, the samples giving the highest reading for TSSApep-III
from Colombia and Venezuela are the same samples that
recognised TSSApep-IV.
Antibodies to the TcII/TcV/TcVI peptide are more
frequent among symptomatic Brazilian patients
60/63 of the Brazilian patients with chronic Chagas disease who
were seropositive against TSSApep-II/V/VI had detailed clinical
evaluation, and of these 60 patients, 23 (38%) had ECG
abnormalities typical of Chagas disease. 23/28 patients seroneg-
ative for TSSApep-II/V/VI also had detailed clinical evaluation,
but in contrast only 4 of these latter, different 23 patients had such
ECG abnormalities (p,0.0001).
Novel bioinformatic algorithms predict highly antigenic
residues
The sequences coding for the TSSA proteins containing the
TSSApep-I and TSSApep-II/V/VI epitopes were subjected to a
Figure 2. Chagasic sera recognise TSSA lineage-specific peptides. Lineage-specific peptides or lysate were added to rows of the ELISA plate
as indicated. ELISA plates showing: recognition of TSSApep-II/V/VI and TSSApep-V/VI, among Brazilian, Ecuadorean and Argentine sera; recognition of
TSSApep-I and TSSApep-IV by an Argentine serum and a Venezuelan serum; recognition of chimera TSSApep-II/I by Argentine sera. All patients were
seropositive with T. cruzi lysate. NEHC = non-endemic healthy control.
doi:10.1371/journal.pntd.0002892.g002
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novel bioinformatic analysis using EpiQuest-B program that builds
the immunogenicity profile for linear protein sequences and
predicts the location and potential immunogenicity of the linear B-
cell epitopes (Litvinov et al, in preparation) in order to give an
antigenicity score for the polymorphic region. The algorithm
predicted high scores within the TSSApep-II/V/VI epitope
region, but much lower for TSSApep-I, as shown in Figure 4.
The different antigenicity scores indicate that the N-terminal
TEN in TSSApep-II/V/VI is the dominant epitope, explaining
the frequent recognition of chimera TSSApep-II/-I (Figure 1)
despite the higher scoring C-terminal GEAPS, which provides a
secondary site of recognition for some (Brazilian) sera that respond
to chimera TSSApep-I/-II (Figure 1). Neither the TEN nor
GEAPS is present in TSSApep-I, explaining the rare recognition
of this epitope. The GEAPS, which is also present in TSSApep-III
and TSSApep-IV, gave much lower antigenicity scores in these
peptides, in the absence of the upstream TEN in these sequences
(data not shown).
Comparative diversity of the putative TcI-applicable
peptide reveals high conservation across lineages
Mendes et al [26] used heterozygous loci in the CL Brener
genome to identify candidate lineage-specific epitopes. One
conserved and three potentially lineage-specific peptides were
synthesised, described as deriving from hypothetical protein
Tc00.1047053510421.310 (conserved epitope peptide), putative
RNA-binding protein Tc00.1047053511837.129 (for TcI serolo-
gy), putative ADP-ribosylation factor GTPase activating protein
Tc00.1047053511589.70 (for TcII), and putative DNA-directed
RNA polymerase III subunit Tc00.1047053510359.320 (for TcVI)
that displayed some discriminatory power in ELISAs and affinity-
ELISAs based on differential range of absorbance values. The
putative TcI epitope was described as restricted to TcI and TcVI
and applicable to serological identification of a specific response to
TcI. We examined the diversity in the coding sequence for this
epitope, using a panel of T. cruzi strains across the lineages
(Table 2). A single amplicon of 381bp was produced by PCR from
all strains using primers MenTcI FOR and MenTcI REV.
Examples from TcI and TcII strains are shown in Figure 5.
However, in comparative sequencing across isolates represent-
ing the lineages we found this epitope to be highly conserved
(Table 2). This epitope had the same amino acid sequence across
all the strains and lineages analysed here with the exception of
strains Y and CBB (TcII) and Para 6 (TcV). In strains Y and CBB,
a heterozygous nucleotide (G/C) residue led to the presence of two
predicted amino acids, Ser or Thr.
The region homologous to the reported TcI-applicable epitope,
which was described as specific to a TcII strain, but given only as
amino acid sequence [26], was subject to BLAST against NCBI
and TriTrypDB databases. There were very low stringency
homologies returned by TriTryp BLAST to various T. cruzi
proteins (mainly around the PPP tripeptide), none of which was
described as RNA-binding proteins. On NCBI BLAST, highest-
scoring matches were to various bacteria and fungi, none to
trypanosomes. Furthermore, none of 55 sera from northern
countries of South America, where TcI is highly endemic, bound
to the TcI synthetic peptide reported in Mendes et al in our
ELISA assays (data not shown).
Discussion
Kong et al [32] developed lineage-specific serology for the
protozoan parasite Toxoplasma gondii, which is difficult to isolate
from chronically infected patients, and most isolates of which are
classified into clonal lineages type I, II, or III. Serology with
synthetic peptides based on diversity within the dense granule
proteins GRA6 and GRA7 was able to distinguish type II from
non-type II infections in humans. Using discriminatory serology, it
was possible to demonstrate that the T. gondii lineages had different
Figure 3. Recognition of TSSA lineage-specific peptides shows a disparate geographical distribution. Each data point represents the
mean A490 of the reaction of duplicates of each serum sample with the peptides. Means of each country data set are represented by solid horizontal
lines; cut-offs, derived from the mean +3SD for each peptide with the EHCs, are shown as dotted line on each graph. Circled and boxed values
indicate the same sera. Resolution for the Brazilian responses to TSSApep-II/V/VI is increased by smaller symbols.
doi:10.1371/journal.pntd.0002892.g003
Lineage-Specific Serology in Chronic Chagas Disease
PLOS Neglected Tropical Diseases | www.plosntds.org 8 May 2014 | Volume 8 | Issue 5 | e2892
continental distributions [33], and that adult offspring of type I-
infected mothers had a significantly increased risk for the
development of psychoses [34].
Here we have used detailed comparative analysis of the genetic
diversity of the T. cruzi TSSA gene encoding the protein core of the
mucin TSSA, to design synthetic peptides for lineage-specific
serology of T. cruzi infection history. These epitopes were
presented on an avidin-coated solid phase via an amino terminal
biotin-label linked to a polyethylene glycol-glycine spacer to
increase rotation and ensure that each amino acid side chain could
freely interact with antibodies. We synthesised and tested these
lineage-specific peptides in ELISA with 186 human sera from six
countries, three in the Southern Cone region of South America
and three in northern South America. We have selected these
countries because typing of T. cruzi isolates with multilocus enzyme
electrophoresis (MLEE) [6], multilocus sequence typing (MLST)
[35] and multilocus microsatellite typing (MLMT) [17] has
repeatedly indicated the predominance of TcII, TcV and TcVI
as the agents of Chagas disease in Southern Cone countries yet the
contrasting high prevalence of TcI in patients North of the
Amazon [7,11]. Nevertheless, there have been some reports that
TcII, as identified by genotyping, can be found among isolates
from humans and domestic triatomine bugs in northern endemic
regions, for example in Colombia and Guatemala [36–38].
Lineage-specific serology is therefore of special interest for T.
cruzi, because of the disparate geographical distributions of both
the T. cruzi lineages and clinical manifestations of chronic Chagas
disease. Thus as long ago as 1981, Miles et al proposed that the
presence of chagasic cardiomyopathy with megaoesophagus and
megacolon in Southern Cone countries, yet apparent absence of
associated megasyndromes from Venezuela, may be related to the
comparative predominance of TcI as the agent of Chagas disease
in northern South America [6]. Nevertheless the evidence of a link
between infecting lineage of T. cruzi and prognosis of chronic
Chagas disease remains circumstantial. As with T. gondii, this is
partly due to the difficulty of isolating and genotyping T. cruzi from
chronic chagasic patients. Blood culture and xenodiagnosis have
limited sensitivity and may be selective for faster growing
biological clones. Furthermore, even if parasites or DNA can be
recovered from chronically infected patients, the resultant T. cruzi
isolates may not be representative of the genetic diversity in the
patient, because T. cruzi replicates intracellularly and lineage
genotypes may be sequestered in the tissues but not recoverable
from the circulating blood [14]. Serology with lineage-specific
antigens provides a means of profiling an individual’s history of T.
cruzi infection, to overcome inaccessibility of the parasite to direct
genotyping during chronic infections.
TSSA provides a good candidate for development of synthetic
peptide-based, lineage-specific serology, because no TSSA homo-
logue beyond the species T. cruzi has been detected by genomic
comparisons, and a lineage-specific candidate epitope can be
represented by a single synthetic peptide. Thus such peptides are
unlikely to generate false positive ELISA results with sera from
endemic healthy controls or from patients with other infectious or
autoimmune diseases. In the multiple ELISAs performed here
none of the healthy controls recognised any of the synthetic
peptides, and all were also serologically negative with the T. cruzi
lysate (Figure 2). However, sera from four of the chagasic patients
bound non-specifically to plates coated with avidin alone and thus
Figure 4. Computer-predicted antigenicity score is much
higher for TSSA-II/V/VI sequence than TSSA-I. Polymorphic
sequences of [A] TSSA-I and [B] TSSA-II/V/VI showing regions of high
antigenicity in red, and low antigenicity in blue. A few amino acid
replacements in TSSA-I lead to disappearance of the immunogenic
epitope that is present in TSSA-II/V/VI sequence.
doi:10.1371/journal.pntd.0002892.g004
Figure 5. PCR amplification of the ORF containing the reported TcI-applicable epitope. Only the amplicon of predicted size (381 bp) was
amplified by the reaction conditions. –ve = no template DNA control. Mk = Hyperladder IV (Bioline, UK).
doi:10.1371/journal.pntd.0002892.g005
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spuriously appeared to recognise all peptides; such artifactual
binding to avidin has been observed in other serological studies
[39].
Since the initial report of the sequence and antigenic
dimorphism of TSSA by Di Noia et al [15], E. coli-produced
recombinant TSSA proteins have been used as antigen with
human and animal sera, as summarised in Table 3. Recognition of
only TSSA-II by chronic chagasic sera from the Southern Cone
region was initially interpreted as suggesting that only TcII caused
chronic Chagas disease [15]. However there are many descriptions
of Chagas disease and chronic chagasic cardiomyopathy in TcI
endemic regions. Recognition of recombinant TSSA-I by human
chagasic sera has been reported by western blot but not by ELISA
[18,21]. One western blot study with recombinant TSSA-II and
TSSA-I has recorded an unexpected level of TcII in northern
South America and Mexico [21]. The recombinant TSSA proteins
used as antigens as described encompass up to 26 amino acids
flanking the polymorphic region [15,20,21], which are highly
conserved between TSSA-I and TSSA-II.
The lineage-specific peptide representing the epitope common
to TcII/TcV/TcVI was recognized by a large number of sera
from Brazil; a proportion of these sera also bound to TSSApep-V/
VI. All duplicate separate samples from the same patients gave
indistinguishable results. The Brazilian sera tested here originated
from the states of Goia´s and Minas Gerais, where TcII human
infections are known to be prevalent, TcV and TcVI are also
present and TcI is (relatively) uncommon [11,40,41], although TcI
is well represented among Brazilian sylvatic transmission cycles
[41,42]. However, a substantial minority of the Brazilian serum
samples (31/98 (31.6%)) did not react with TSSApep-II/V/VI.
Thus sensitivity of the TSSApep-II/V/VI ELISA does not appear
to be absolute for TcII/TcV/TcVI T. cruzi infections (Figure 2,
Table 1). It is possible that corresponding antibodies in the TcII/
TcV/TcVI seronegative patients were simply below the threshold
for detection in the ELISA, although this seems unlikely because
such patients remained equally seronegative against the peptides
even when re-tested at the higher serum concentration of 1:100
(data not shown). Alternatively, some patients may fail to generate
an immune response to the epitope or there may be as yet
undiscovered TSSA diversity in some T. cruzi TcII strains.
Elsewhere in the Southern Cone countries 12 of 15 sera from
Bolivia or Argentina were seropositive with TSSApep-II/V/VI, in
accord with the known high prevalence of these lineages in those
countries [23]. All sera from Bolivia, Argentina and Ecuador, and
the great majority of those from Brazil, that recognised TSSApep-
II/V/VI also reacted with chimera TSSApep-II/-I indicating that
crucial residues reside in the N-terminal part of the TSSA-II/V/
VI epitope.
We found that few serum samples from the three countries in
northern South America recognized TSSApep-II/V/VI or
TSSApep-V/VI. This is consistent with the literature on the
geographical distribution of T. cruzi lineages based on genotyping
of isolates from domestic and sylvatic transmission cycles. In fact
only 4 sera from Ecuador were seropositive with TSSApep-II/V/
VI out of 66 from these northern countries. At least 3 of these 4
Ecuadorian serum samples originated from the Loja region in
southern Ecuador, where TcI has been isolated [43], close to the
border with Peru. Risso et al [21] reported the identification of
TcII in Colombia, Venezuela, and Mexico using western blots
with TSSA-II recombinant antigen. However, when the same
Colombian sera samples were tested here using the lineage-specific
peptides we found no TSSApep-II/V/VI seropositive patients.
Thus with our data we are unable to confirm the presence of
TcII/TcV/TcVI in those Colombian patients.
Only four sera, including one from Venezuela where TcIV is
known to sporadically infect humans, recognised TSSApep-IV. All
four sera also recognised TSSApep-III, which shares 14 of 16
residues, presumably due to cross reaction, as we have observed
with experimental murine sera (Bhattacharyya et al, in prepara-
tion).
Apart from one Argentine and one Brazilian serum, no clear
specific reaction with TSSApep-I was observed, even with sera
from known TcI endemic regions in Venezuela, Colombia and
Ecuador. The few TSSApep-II/V/VI seropositive samples from
Brazil that also reacted with chimera TSSApep-I/-II did not react
with TSSApep-I. One possibility is that the TSSA-I protein, if
expressed at all in chagasic patients, is not sufficiently immuno-
genic to generate an antibody response, possibly due to post-
translational glycosylation of the core peptide sequence. Identifi-
cation of the disaccharide Gala(1,3)Galb as the immunodominant
glycotope present in the O-linked mucins, i.e., those glycosylated
on serine or threonine residues of the peptide chain, has been
reported recently [44,45], and both serine and threonine are
represented by one additional residue in TSSApep-I as compared
Table 3. Reports of TSSA recombinant proteins in serological assays.
Reference
rTSSA Tc
lineage Assay Sources of human sera Authors’ reports
[15] I, II ELISA, CL-ELISAa Argentina, Brazil, Chile TSSA dimorphism; chagasic sera only recognise rTSSA-II; TcI or TcII -infected animal sera
recognised the homologous rTSSA form, without cross-reactivity.
[18] I, II/V/VI Western blot Argentina TcII/V/VI and TcI co-infection in cases of chagasic cardiomyopathy; TcII/V/VI also in
indeterminate clinical form.
[19] II ELISA Argentina rTSSA-II recognised by chagasic but not non-chagasic or cutaneous leishmaniasis sera.
rTSSA-II recognised by canine sera from TcVI but not TcI or TcIII infections.
[20] IIb CL-ELISA a Brazil rTSSA-II 98% sensitive; no response to rTSSA-I; minimal cross-reactivity with Leishmania
sera.
[21] I, II Western blot Argentina, Colombia, Mexico,
Paraguay, Venezuela
Recognition of TSSA-II, TSSA-I and TSSA-II/I in northern South America and Mexico;
almost exclusively rTSSA-II in southern South America.
[22] I, II/V/VI Western blot,
ELISA
Argentina, Bolivia, Paraguay TcII/V/VI predominant in pregnant chagasic women; no recognition of TSSA-I reported.
[23] IIb ELISA Argentina TcII and/or TcV/TcVI in the north of Salta province.
aChemiluminescent ELISA; bcalled by authors TSSA VI, but the same as that first described as TSSA-II.
doi:10.1371/journal.pntd.0002892.t003
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with the TSSA-II epitope. However, equally likely, the TSSA I
epitope may be conformational, with a structure that is not
represented by the linear peptide. Also, alternative immunodomi-
nant epitopes elsewhere in TSSA-I may skew the humoral
response away from the sequence represented by TSSApep-I.
We were interested to see whether there was a difference in the
proportions of TSSApep-II/V/VI seropositive and seronegative
patients presenting with clinical symptoms of chronic Chagas
disease. Remarkably, there was a clear statistically significant
difference: 23/60 (38%) of the Brazilian TSSApep-II/V/VI
seropositives had ECG abnormalities typical of Chagas disease,
whereas such abnormalities only occurred in 4/23 (17%) of the
seronegatives (p,0.0001). One possible interpretation of these
data is that TSSApep-II/V/VI seronegative patients may not be
infected with these lineages but with some less pathogenic strains.
Alternatively, such seronegative patients may be infected with
TcII, TcV or TcVI but the absence of an immune response to the
TSSA-II/V/VI common epitope may be an indicator of a long
term better prognosis; however confirmation would require a
more extensive and longitudinal study. However, the frequencies
of megaoesophagus (43% vs 48%) and megacolon (10% vs 8.7%)
were not significantly different between the TSSApep-II/V/VI
seropositive and seronegative groups respectively.
Trypanosoma rangeli is non-pathogenic to humans, is found
sympatric with T. cruzi, particularly in northern South America,
and serological cross-reaction between these species has been
recognised [46]. The divergence of the TSSA epitopes in T. cruzi
and the lack of response to the peptides with sera from northern
South America, indicate that monospecific sera from patients
infected with T. rangeli alone will not recognise these synthetic
peptide epitopes.
A recent paper reported the identification of a TcI epitope for
lineage-specific serology [26]. However, upon analysing the
sequence diversity in the ORF coding for the parent protein
across T. cruzi lineages, in contrast we found a very high degree of
sequence conservation across the lineages. Thus, we were not able
to confirm any TcI-specificity of that peptide epitope.
We have demonstrated that synthetic peptides are able to
provide T. cruzi antigens for lineage-specific serological diagnosis
in chronic Chagas disease. Synthetic-peptide based lineage-specific
serology has also confirmed the disparate geographical distribution
of TcII/TcV/TcVI but found fewer TcII infections in northern
South America than reported with western blots and recombinant
TSSA-II. Further comparisons of recombinant TSSA antigens and
synthetic peptides are indicated. More attempts should be made to
design a TcI specific peptide, and by comparative genomics to seek
alternative antigens to TSSA that may be lineage-specific.
However, such in silico methods will need to incorporate structural
analysis, and if necessary devise linear peptides that represent
conformational epitopes. In a region of Brazil endemic for TcII we
find a higher rate of ECG abnormalities among patients with
TSSApep-II/V/VI seropositivity than among seronegative pa-
tients. Synthetic-peptide antigens clearly have substantial and
versatile potential in studying the relationship between a patient’s
history of infection and clinical status, and they may provide
clinical biomarkers for prognosis of Chagas disease.
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